The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids

This study has been completed.
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Radboud University
ClinicalTrials.gov Identifier:
NCT00184899
First received: September 12, 2005
Last updated: February 28, 2007
Last verified: February 2007
  Purpose

The metabolic syndrome is associated with hyperdynamic circulation and sympathetic activation. Recently, Bakker et al. (Atherosclerosis 2002) described the hypothesis that free fatty acids are responsible for this association. The investigators hypothesize that in patients with obesity and the metabolic syndrome, an increased intracellular concentration of long-chain fatty acyl (LCFA)-CoA (the intracellular equivalent of free fatty acids) induces an increase in adenosine. Adenosine receptor stimulation, in turn, induces vasodilation and sympathetic activation.

The investigators aimed to assess this effect of free fatty acids on the adenosine system in healthy volunteers.


Condition Intervention
Obesity
Metabolic Syndrome X
Drug: Intravenous infusion of Intralipid/heparin
Drug: Intravenous infusion of Glycerol/heparin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Educational/Counseling/Training
Official Title: The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids

Resource links provided by NLM:


Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Forearm blood flow
  • Vasoactive effect of caffeine
  • Sympathetic activity (noradrenaline spillover, spectral analysis)

Estimated Enrollment: 20
Study Start Date: August 2005
Estimated Study Completion Date: August 2006
  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers

Exclusion Criteria:

  • Pregnancy
  • Asthma
  • Use of medication
  • Cardiovascular/pulmonary disease and diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184899

Locations
Netherlands
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500HB
Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Principal Investigator: Paul Smits, MD, PhD Radboud University
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00184899     History of Changes
Other Study ID Numbers: Intralipid-Ado, ZonMw Nr. 920-03-249
Study First Received: September 12, 2005
Last Updated: February 28, 2007
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:
free fatty acids
vasodilation
sympathetic activity

Additional relevant MeSH terms:
Obesity
Metabolic Syndrome X
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Adenosine
Heparin
Calcium heparin
Glycerol
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anti-Arrhythmia Agents
Cardiovascular Agents
Vasodilator Agents
Cryoprotective Agents
Protective Agents
Anticoagulants
Hematologic Agents
Fibrinolytic Agents

ClinicalTrials.gov processed this record on August 21, 2014